Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 6/20 | 0.54 |
| ▸ | DRD2 | P14416 | 5/20 | 0.54 |
| ▸ | DRD3 | P35462 | 4/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 2/20 | 0.50 |
| ▸ | NCF1 | P14598 | 1/20 | 0.50 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.48 |
| ▸ | HTR3B | O95264 | 1/20 | 0.48 |
| ▸ | HTR3A | P46098 | 1/20 | 0.48 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.48 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6194016 | 0.84 | HTR1A (0.64) | DRD4DRD2DRD3HTR1ANCF1 | |
| SCHEMBL10528138 | 0.80 | KMT2A (0.56) | DRD4DRD2DRD3HTR1ANCF1 | |
| SCHEMBL6811181 | 0.77 | ALDH1A1 (0.50) | DRD2MAPK1HTR1ANCF1HTR3E | |
| SCHEMBL14493421 | 0.77 | DRD4 (0.49) | DRD4DRD2DRD3MAPK1NCF1 | |
| SCHEMBL6864559 | 0.77 | DRD2 (0.65) | DRD4DRD2DRD3MAPK1KMT2A | |
| SCHEMBL6793112 | 0.76 | DRD2 (0.63) | DRD4DRD2DRD3HTR1A | |
| SCHEMBL13568797 | 0.75 | ALDH1A1 (0.71) | DRD4DRD2DRD3MAPK1TDP1 | |
| SCHEMBL6418686 | 0.75 | HTR1A (0.64) | DRD4DRD2DRD3HTR1ANCF1 | |
| SCHEMBL16225922 | 0.75 | ALDH1A1 (0.74) | KMT2ASIGMAR1 | |
| SCHEMBL5369021 | 0.75 | HTR6 (0.66) | HTR1ANCF1HTR3EHTR3BHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269246-A1 | METHOD FOR TREATING PEDIATRIC BIPOLAR DISORDER | PFIZER INC | 2008-10-30 | — | — | US | disclosed |
| EP-1757292-A1 | Method of treating ocd and tic disorders | Pfizer Products Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1633361-A1 | ANXIETY TREATMENTS WITH ZIPRASIDONE | Pfizer Products Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1633360-A1 | TREATMENT OF PSYCHOTIC AND DEPRESSIVE DISORDERS | Pfizer Products Incorporated (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1626722-A1 | METHOD FOR ENHANCING COGNITION USING ZIPRASIDONE | Pfizer Products Inc. (US) | 2006-02-22 | — | — | EP | disclosed |
| EP-1626723-A1 | TREATMENT OF BIPOLAR DISORDERS AND ASSOCIATED SYMPTOMS | Pfizer Products Inc. (US) | 2006-02-22 | — | — | EP | disclosed |
| US-20050038036-A1 | Stabilization patient; antidepressant; psychological disorders; mood cycles | PFIZER INC | 2005-02-17 | — | — | US | disclosed |
| US-20050014764-A1 | Method for enhancing cognition using ziprasidone | PFIZER INC | 2005-01-20 | — | — | US | disclosed |
| US-20050004138-A1 | Anxiety treatments with ziprasidone | PFIZER INC | 2005-01-06 | — | — | US | disclosed |
| US-20050004137-A1 | Treatment of psychotic and depressive disorders | PFIZER INC | 2005-01-06 | — | — | US | disclosed |
| EP-0985414-A2 | Method of treating glaucoma and ischemic retinopathy | Pfizer Products Inc. (US) | 2000-03-15 | — | — | EP | disclosed |
| EP-0931547-A1 | Piperazinyl-heterocyclic compounds in the treatment of psychiatric conditions | Pfizer Products Inc. (US) | 1999-07-28 | — | — | EP | disclosed |
| EP-0901789-A1 | Method of treating tourette's syndrome | Pfizer Products Inc. (US) | 1999-03-17 | — | — | EP | disclosed |
| EP-0279598-B1 | ARYLPIPERAZINYL-ALKYLENE-PHENYL-HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 1993-09-15 | — | — | EP | disclosed |
| EP-0281309-B1 | PIPERAZINYL-HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 1991-12-27 | — | — | EP | disclosed |
| US-4891375-A | Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds | PFIZER INC. (US) | 1990-01-02 | — | — | US | disclosed |
| US-4883795-A | Piperazinyl-heterocyclic compounds | PFIZER INC. (US) | 1989-11-28 | — | — | US | disclosed |
| US-4831031-A | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity | PFIZER INC. (US) | 1989-05-16 | — | — | US | disclosed |
| EP-0281309-A1 | Piperazinyl-heterocyclic compounds | PFIZER INC. (US) | 1988-09-07 | — | — | EP | disclosed |
| EP-0279598-A2 | Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds | PFIZER INC. (US) | 1988-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004137-A1 | Treatment of psychotic and depressive disorders | SNCA, NLN, INA | DRD4 150/4885DRD2 355/4885DRD3 392/4885 |
| US-20050038036-A1 | Stabilization patient; antidepressant; psychological disorders; mood cycles | MC2R, NR3C1, CRH | DRD4 172/4885DRD2 199/4885DRD3 131/4885 |
| US-20050014764-A1 | Method for enhancing cognition using ziprasidone | DBH, RAP1A, GABRR1 | DRD4 365/4885DRD2 130/4885DRD3 241/4885 |
| US-20080269246-A1 | METHOD FOR TREATING PEDIATRIC BIPOLAR DISORDER | GABBR1, GABRR1, GABBR2 | DRD4 385/4885DRD2 145/4885DRD3 200/4885 |
| US-20050004138-A1 | Anxiety treatments with ziprasidone | NPSR1, AVPR1B, SLC39A3 | DRD4 874/4885DRD2 255/4885DRD3 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.